UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): August 6, 2020 (August 4, 2020)
THERAPEUTICS ACQUISITION CORP.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of
incorporation) | | 001-39373
(Commission File Number) | | 85-0800493
(I.R.S. Employer Identification No.) |
| |
200 Berkeley Street
18th Floor
Boston, MA (Address of principal executive offices) | 02116
(Zip Code) |
(617) 778.2500
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencements communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | | Trading Symbols | | Name of each exchange on
which registered |
| | | | | |
Class A common stock, par value
$0.0001 per share | | TXAC | | The Nasdaq Capital Market |
| x | Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). |
| ¨ | If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. |
On August 4, 2020, Therapeutics Acquisition Corporation (the “Company”) filed a d/b/a with the Secretary of State of the State of Delaware to operate as Research Alliance Corp. I.
In connection with the filing of the d/b/a, the Company is changing its ticker symbol on the Nasdaq Capital Market from “TXAC” to “RACA.” Trading under the new ticker symbol is expected to commence on August 7, 2020.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | |
| | Therapeutics Acquisition Corp. |
| | |
| Date: August 6, 2020 | By: | /s/ Matthew Hammond |
| | Name: | Matthew Hammond |
| | Title: | Chief Financial Officer |
